Personalis
Personalis is recorded as a service provider in 60 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 60 trials · Latest update first
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Sponsor Bioinvent International AB
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 12 centers in Europe and the United States, of which 8 centers enrolled participants.
- Forty-two participants were screened by 9 sites, and 35 participants were enrolled over approximately 16 months.
- The planned Phase 2a part was not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Sponsor Moderna Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
B1931036 - A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH- RISK OR VERY HIGH-RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors
Sponsor Larkspur Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
MAGNETISMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy Including Lenalidomide and a Proteasome Inhibitor
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (INTerpath-001)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Personalis?
The 2026-10-09 snapshot links Personalis to 60 distinct CTIS trials. Recorded services include Laboratory services, ctDNA in blood and DNA in tumor, Analytical lab of blood for DNA analysis, fresh blood biopsy, archival tumor blocks/slides, Bioanalytical lab, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Personalis?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gynecology, Urology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Personalis conducted?
The linked trials record locations in 24 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Personalis delivered services.
What can this page tell me about Personalis's trial experience?
Browse 60 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Personalis. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Personalis
- Personalis Inc.